Jacob Fund released its third-quarter 2025 investor letter, citing market recovery and new all-time highs in equity indexes. Tariffs had limited economic impact, stabilizing the market. The fund anticipates a new productivity cycle to boost profit margins. Top holdings and picks for 2025 can be reviewed.

Omeros Corporation (NASDAQ: OMER) was highlighted in the investor letter, showing a 64.39% one-month return. With a market capitalization of $769.27 million, the stock closed at $10.85 on December 5, 2025. The fund added Omeros as a new position, citing strong approval chances for its monoclonal antibody product.

Despite being held by 14 hedge fund portfolios at the end of the third quarter, Omeros Corporation (NASDAQ: OMER) is not among the 30 most popular stocks among hedge funds. The fund acknowledges Omeros’ potential but believes certain AI stocks offer better upside potential with less downside risk. Investors can explore a free report on the best short-term AI stock.

Read more at Yahoo Finance: Do You Believe Omeros Corporation’s (OMER) New Monoclonal Antibody Has Strong Chances of Approval?